SWOG clinical trial number
SWOG-9321
Standard Dose Versus Myeloablative Therapy For Previously Untreated Symptomatic Multiple Myeloma
Abbreviated Title
Previously Untreated MM
Participants
NCORP, Limited Institutions: SWOG Approved Autologous BMT Facilities,
Members, ECOG, CALGB
Treatment
Cyclophosphamide
Prednisone
BCNU
Cyclosporine
Filgrastim
Intron A
Melphalan
Mesna
Methotrexate
VAD
Newly diagnosed active Multiple Myeloma (MM); smoldering myeloma allowed if evidence of progressive disease requiring chemo.; protein criteria must be present; non-secretory patients are eligible if the patient has > or = 30% plasmacytosis; no prior chemo. for myeloma; prior RT for isolated plasmacytomas allowed if cumulative total doses do not exceed limits specified in protocol; patients must < / or = 70 years of age; SWOG PS 0-2 (but PS of 3-4 is allowed if based solely on bone pain); submission of pre-treatment bone marrow aspirate, paraffin block, and serum is mandatory; no significant co-morbid medical conditions, or uncontrolled life-threatening infection or uncontrolled diabetes allowed; patient must have adequate cardiac function, no history of COPD or chronic cerebral vascular accident; patients with renal failure, even if on dialysis, are eligible if it is felt to be due to the myeloma and if duration of renal failure does not exceed 2 months; financial clearance for transplant must be obtained prior to randomization.
2011
Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examing whether different variables govern different time segments of survival [PMID21153898;PMC3053415]
B Barlogie;V Bolejack;M Schell;J Crowley Annals of Hematology 90(4):423-428
2010
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences [PMC2834471;
PMID20085933]
B Barlogie;M Attal;J Crowley;F van Rhee;J Szymonifka;P Moreau;B Durie;J Harosseau Journal of Clinical Oncology 28(7):1209-1214
2009
Long-term follow-up of autotransplant (AT)-supported high-dose melphalan (hdm) for multiple myeloma (MM): update of Intergroup Francophone du Myeloma (IFM), Southwest Oncology Group (SWOG), and Arkansas (ARK) Total Therapy (TT) trials
B Barlogie;M Attal;J Crowley;J Harousseau Journal of Clinical Oncology 27:15s, abst. #8519
Prognostic factor analyses of myeloma (MM) survival outcomes on intergroup trial S9321 (int 0141): examining whether different variables govern different time segments of survival
J Crowley;V Bolejack;K Robert;K Anderson;B Barlogie Journal of Clinical Oncology 27:15s, abst. #8599
Genetic polymorphisms of EPHX1, Gsk3B, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma
B Durie;B Van Ness;C Ramos;O Stephens;M Haznadar;A Hoering;J Haessler;M Katz;G Mundy;R Kyle;GA Morgan;J Crowley;B Barlogie;J Shaughnessy Leukemia 23(10):1913-1919
2008
Analytical approaches for the BOAC SNP panel association with progression free survival in myeloma
B Van Ness;C Ramos;VK Kumar;M Steinbach;B Durie;J Crowley;B Barlogie;A Hoering;J Haessler;DC Johnson;G Morgan Blood 112:abst.#2715
Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival [PMID18778477; PMC2553089]
B Van Ness;C Ramos;M Haznadar;A Hoering;J Haessler;J Crowley;S Jacobus;M Oken;V Rajkumar;P Greipp;B Barlogie;B Durie;G Atluri;G Fang;R Gupta;M Steinbach;V Kumar;R Mushlin;D Johnson;G Morgan BMC Medicine 6:26
2006
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321
B Barlogie;RA Kyle;KC Anderson;PR Greipp;HM Lazarus;DD Hurd;J McCoy;DF Moore Jr;SR Dakhil;KS Lanier;RA Chapman;JN Cromer;SE Salmon;B Durie;JJ Crowley Journal of Clinical Oncology 24(6):929-936
2005
Incidence, outcomes, and SNP genotypes show different ethnic association in patients with myeloma, assessed in SWOG and ECOG clinical trials S9321 and E9486: from the Bank on a Cure
B Van Ness;J Crowley;C Ramos;S Grindle;E Rasmussen;E Blood;A Hoering;B Barlogie;P Greipp;B Durie Blood (ASH Annual Meeting Abstracts) 106(11): #506
SNP genotypes show association with common toxicities during both VAD induction and high dose melphalan with autologous transplant support in Intergroup trial S9321 for myeloma: from the bank on a cure
BG Van Ness;JC Crowley;C Ramon;S Grindle;E Rasmussen;A Hoering;P Greipp;B Barlogie;B Durie Blood (ASH Annual Meeting Abstracts) 106(11): #3488
SNP genotypes as prognostic factors associated with staging in myeloma: the first combined SNP association analysis of SWOG, ECOG, and MRC clinical trials from the Bank on a Cure
B Van Ness;J Crowley;E Blood;E Rasmussen;C Ramos;S Grindle;G Morgan;D Johnson;A Hoering;P Greipp;B Barlogie;B Durie Blood (ASH Annual Meeting Abstracts) 106(11): #3489
2004
Genetic polymorphisms associated with clinical outcome in the Intergroup trial S9321, comparing high dose therapy with standard dose therapy for myelomaon, on behalf of ECOG, SWOG, CALGB, and the bank on a cure
R Santana-Davila;J Crowley;B Durie;B Barlogie;P Greipp;B Van Ness Blood 104(11): #1495
Comparable survival in newly diagnosed multiple myeloma (MM) after VAD induction with high dose therapy using melphalan 140mg/m2 + TBI 12 Gy (MEL + TBI) versus standard therapy with VBMCP and no benefit from interferon (IFN) maintenance: final clinical results of intergroup trial S9321 in the context of IFM 90 and MRC
J Crowley;R Fonseca;P Greipp;J McCoy;B Barlogie Blood 104(11): #539
Extreme regression: a statistical technique for finding good or poor prognostic groups, illustrated using myeloma patient data from Intergroup trial S9321
JJ Crowley;J McCoy;M LeBlanc;B Barlogie Blood 104(11): #5202
2003
Southwest Oncology Group studies in bladder cancer
ED Crawford;DP Wood;DP Petrylak;J Scott;CA Coltman, Jr;D Raghavan Cancer Supplement 97(8):2099-2108
Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg/m2 + TBI 12 Gy autotransplants versus standrad dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: results of Intergroup trial S9321
B Barlogie;R Kyle;K Anderson;P Greipp;H Lazarus;J Jacobson;E Rasmussen;J Cromer;J Crowley Blood 102(11):(#135)
2002
A simple classification to identify poor-risk untreated myeloma
PR Greipp;S Kumar;EA Blood;M Rue;J Jacobson;TM Therneu;DR Larson;KC Ancerson;MM Oken;RA Kyle Blood 100(11):598a(#2351)
2000
A protocol for triple color interphase FISH on archived bone marrow biopsies from myeloma prepared with precipitating fixatives
E Tian;K Bumm;Y Xiao;H Xu;A Li;E Williamson;B Barlogie;J Sawyer;J Shaughnessy Blood 96(11):155a(#665)
BETA 2 microglobulin (O2M) and plasma cell labeling index (PCLI) constitute a strong prognostic index in the SWOG Intergroup transplant trial S9321: Observations on gender and age
PR Greipp;JL Jacobson;JJ Crowley;KJ Henderson;KC Anderson;RA Kyle;B Barlogie Blood 96(11):152a(#653)
1999
Planned melphalan-total body irradiation (MEL-TBI) - based allogeneic transplantation for multiple myeloma (MM) up t age 55: an intergroup experience (CALGB, ECOG and SWOG) under the auspices of the Southwest Oncology Group (SWOG 9321)
R Desika;S Salmon;K Anderson;R Kyle;J Crowley;B Barlogie Blood 94(10)Suppl.1:346a(#1546)part_1_of_2
The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma
LM Rimsza;K Campbell;WS Dalton;S Salmon;G Willcox;TM Grogan Leukemia and Lymphoma 34(3-4):315-324
